PMID- 35338446
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 13
IP  - 5
DP  - 2022 May
TI  - Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical 
      Complications.
PG  - 873-888
LID - 10.1007/s13300-022-01237-9 [doi]
AB  - Dapagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2i) 
      indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure 
      (HF) with reduced ejection fraction (EF) and chronic kidney disease (CKD). In 
      monotherapy or as an additive therapy, dapagliflozin aids glycaemic control, is 
      associated with reductions in blood pressure and weight, and promotes a 
      favourable lipid profile. In this review, we address the impact of dapagliflozin 
      on cardiovascular risk factors and common microangiopathic complications such as 
      kidney disease and retinopathy in patients with T2DM. Furthermore, we evaluate 
      its potential beneficial effects on other less frequent complications of 
      diabetes, such as macular oedema, cognitive impairment, non-alcoholic fatty liver 
      disease and respiratory disorders during sleep. Moreover, the underuse of SGLT2i 
      in clinical practice is discussed. Our goal is to help translate this evidence 
      into clinical practice.
CI  - (c) 2022. The Author(s).
FAU - Bellido, Virginia
AU  - Bellido V
AD  - Endocrinology and Nutrition Department, Virgen del Rocio University Hospital, 
      Sevilla, Spain.
FAU - Martinez, Julia
AU  - Martinez J
AD  - Medical Department, AstraZeneca Spain, Madrid, Spain.
FAU - Calvo, Fernando
AU  - Calvo F
AD  - Endocrinology and Nutrition Department, "Lozano Blesa" Clinical Hospital, 
      Zaragoza, Spain.
FAU - Villarroel, Aida
AU  - Villarroel A
AD  - Medical Department, AstraZeneca Spain, Madrid, Spain.
FAU - Lecumberri, Edurne
AU  - Lecumberri E
AD  - Endocrinology and Nutrition Department, Ramon y Cajal University Hospital, 
      Madrid, Spain.
FAU - Moreno, Juan
AU  - Moreno J
AD  - Medical Department, AstraZeneca Spain, Madrid, Spain.
FAU - Morillas, Carlos
AU  - Morillas C
AD  - Endocrinology and Nutrition Department, Dr Peset University Hospital of Valencia, 
      Valencia, Spain.
FAU - Rodrigo, Silvia
AU  - Rodrigo S
AD  - Medical Department, AstraZeneca Spain, Madrid, Spain.
FAU - Izarra, Aitziber
AU  - Izarra A
AD  - Medical Department, AstraZeneca Spain, Madrid, Spain.
FAU - Lecube, Albert
AU  - Lecube A
AD  - Research Group On Obesity, Diabetes and Metabolism (ODIM), Institute of 
      Biomedical Research of Lleida (IRBLleida), Endocrinology and Nutrition 
      Department, Arnau de Vilanova University Hospital, Lleida, University of Lleida, 
      Avda. Rovira Roure 80, 25198, Lleida, Spain. alecube@gmail.com.
AD  - Biomedical Research Networking Center in Diabetes and Associated Metabolic 
      Disorders (CIBERDEM), Carlos III Health Institute, Madrid, Spain. 
      alecube@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220325
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC9076778
OTO - NOTNLM
OT  - Cardiometabolic risk factors
OT  - Dapagliflozin
OT  - Diabetes mellitus
OT  - Diabetic angiopathy
OT  - Sodium-glucose cotransporter 2 inhibitors
OT  - Therapeutic inertia
EDAT- 2022/03/27 06:00
MHDA- 2022/03/27 06:01
PMCR- 2022/03/25
CRDT- 2022/03/26 05:31
PHST- 2021/12/06 00:00 [received]
PHST- 2022/02/21 00:00 [accepted]
PHST- 2022/03/27 06:00 [pubmed]
PHST- 2022/03/27 06:01 [medline]
PHST- 2022/03/26 05:31 [entrez]
PHST- 2022/03/25 00:00 [pmc-release]
AID - 10.1007/s13300-022-01237-9 [pii]
AID - 1237 [pii]
AID - 10.1007/s13300-022-01237-9 [doi]
PST - ppublish
SO  - Diabetes Ther. 2022 May;13(5):873-888. doi: 10.1007/s13300-022-01237-9. Epub 2022 
      Mar 25.